3 ms·
For every new drug that starts in academia, a pharma has optimized that molecule / biological to maximize efficacy and reduce toxicity, always incurring major e
by randcraw 7y ago
For every new drug that starts in academia, a pharma has optimized that molecule / biological to maximize efficacy and reduce toxicity, always incurring major expense to do so, 90% of the time ending in failure.
Like most 'successes', new drugs arise due much more to grunt perspiration (and regulation) at a pharma, than due to inspiration by a genius inventor — despite what industry outsiders may want to believe.
- Retric 7y agoThat optimization generally starts in tiny biotech companies not the industry behemoths. What they lack is less research prowess than the ability to efficiently market to doctors. Thus the win/win of the big guy’s constantly buying up other companies. Granted, the equilibrium is generally for small companies to try and sell early when some risk still exists.